The city of Boca Raton, Florida, currently has 16 active clinical trials seeking participants for Parkinson's Disease research studies.
Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease
NCT05766813
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in patients with a diagnosis of Parkinson's Disease consistent with the UK Parkinson's Disease Society (UKPDS) Brain Bank diagnostic criteria, who are experiencing wearing off symptoms and levodopa-induced dyskinesia.
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
10/20/2023
Locations: Clinical Site, Boca Raton, Florida
Conditions: Parkinson Disease
Register for Updates
Noninterventional Study Evaluating Parkinson's Disease Diary Use
NCT05363046
Recruiting
This study aims to evaluate the impact of the frequency of assessments on the variability over time, reliability, and compliance for the Parkinson's disease (PD) diary in patients with PD in whom medications do not provide adequate control of symptoms.
Gender:
All
Ages:
Between 39 years and 70 years
Trial Updated:
09/12/2023
Locations: Movement Disorders Center of Boca Raton, Boca Raton, Florida
Conditions: Parkinson's Disease
Register for Updates
Outcomes Mandate National Integration With Cannabis as Medicine
NCT03944447
Recruiting
This will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.
Gender:
All
Ages:
7 years and above
Trial Updated:
05/29/2022
Locations: OMNI Medical Services, Boca Raton, Florida
Conditions: Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury, Chronic Pain Due to Trauma, Fibromyalgia, Seizures, Hepatitis C, Cancer, Crohn Disease, HIV/AIDS, Multiple Sclerosis, Traumatic Brain Injury, Sickle Cell Disease, Post Traumatic Stress Disorder, Tourette Syndrome, Ulcerative Colitis, Glaucoma, Epilepsy, Inflammatory Bowel Diseases, Parkinson Disease, Amyotrophic Lateral Sclerosis, Chronic Traumatic Encephalopathy, Anxiety, Depression, Insomnia, Autism, Opioid-use Disorder, Bipolar Disorder, Covid19, SARS-CoV Infection, COVID-19, Corona Virus Infection, Coronavirus
Register for Updates
Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy
NCT04857359
Recruiting
This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients with dyskinesia (randomized 1:1 to receive active or placebo) for 12 weeks (1 week at 150 mg per day and 11 weeks at 300 mg per day). The primary efficacy assessment will be based on the Unified Dyskinesia Rating Scale (UDysRS). Patients who complete the 12-week blinded treatment period may have the option to roll into an open-label safety extension study for an additional 12-month treatment period.
Gender:
All
Ages:
Between 30 years and 85 years
Trial Updated:
05/18/2022
Locations: Parkinson's Disease and Movement Disorders Center of Boca Raton Inc, Boca Raton, Florida
Conditions: Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias
Register for Updates